Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 47,200 shares, a growth of 38.4% from the September 15th total of 34,100 shares. Based on an average daily volume of 41,000 shares, the days-to-cover ratio is currently 1.2 days.
A hedge fund recently bought a new stake in Entera Bio stock. Virtu Financial LLC acquired a new stake in Entera Bio Ltd. (NASDAQ:ENTX - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 22,040 shares of the company's stock, valued at approximately $37,000. 14.11% of the stock is currently owned by hedge funds and other institutional investors.
Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Entera Bio in a research note on Monday, October 7th.
Get Our Latest Analysis on Entera Bio
NASDAQ:ENTX traded up $0.08 during trading hours on Friday, reaching $1.86. The company had a trading volume of 41,695 shares, compared to its average volume of 127,052. The firm has a market cap of $66.56 million, a PE ratio of -6.64 and a beta of 1.57. Entera Bio has a 1-year low of $0.52 and a 1-year high of $3.35. The business's 50 day moving average price is $1.79 and its 200-day moving average price is $1.97.
Entera Bio (NASDAQ:ENTX - Get Free Report) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The business had revenue of $0.06 million during the quarter. On average, analysts expect that Entera Bio will post -0.23 earnings per share for the current fiscal year.
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.